Expression Order of Alpha-v and Beta-3 Integrin Subunits in the N-Methyl-N-Nitrosourea-Induced Rat Mammary Tumor Model

REFERENCES

• Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673–687
   PubMed Web of Science ®Google Scholar
• Allen C. M., Sharman W. M., Madeleine C. L., Van Lier J. E., Weber J. M. Attenuation of photodynamically induced apoptosis by an RGD containing peptide. Photochem Photobiol Sci 2002; 1: 246–254
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999; 76: 1–20
   PubMed Web of Science ®Google Scholar
• Eliceiri B. P., Cheresh D. A. The role of alpha v beta 3 integrins during angiogenesis. J Clin Invest 1999; 103: 1227–1230
   PubMed Web of Science ®Google Scholar
• Boettiger D., Lynch L., Blystone S., Huber F. Distinct ligand-binding modes for integrin αvβ3-mediated adhesion to fibronectin vs vitronectin. J Biol Chem 2001; 276(34)31684–31690
   PubMed Web of Science ®Google Scholar
• Maubant S., Cruet-Hennequart S., Dutoit S., Denoux Y., Crouet H., Amar M. A., Gauduchon P. Expression of αv-associated integrin β subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J M Histol 2005; 36(1–2)119–129
   PubMed Web of Science ®Google Scholar
• Sigstad E., Dong H. P., Nielson S., Berner A., Davidson B., Rinsberg B. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol 2004; 33(5)325–331
   Web of Science ®Google Scholar
• Gui G. P., Wells C. A., Yeomans P., Jordan S. E., Vinson G. P., Carpenter R. Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. Surg Oncol 1996; 22(3)254–258
   Web of Science ®Google Scholar
• Edlund M., Miyamoto T., Sikes R. A., Ogle R., et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 2001; 12(2)99–107
   PubMedGoogle Scholar
• Boppart S. A., Oldenburg A. L., Xu C., Marks D. L. Optical probes and techniques for molecular contrast enhancement in coherence imaging. J Biomed Opt 2005; 10(4)0412081–04120814
   Google Scholar
• Oldenburg A. L., Toublan F. J.J., Suslick K. S., Wei A., Boppart S. A. Magnetomotive contrast for in vivo optical coherence tomography. Opt Expr 2005; 13(17)6597–6614
   PubMed Web of Science ®Google Scholar
• Tobulan F. J.J., Boppart S. A., Suslick K. S. Tumor targeting by surface-modified protein microspheres. J Am Chem Soc 2006; 128: 3472–3473
   PubMed Web of Science ®Google Scholar
• Zysk A. M., Nguyen F. T., Oldenburg A. L., Marks D. L., Boppart S. A. Optical coherence tomography: a review of clinical application development from bench to bedside. J Biomed Opt 2007; 12: 051403
   PubMed Web of Science ®Google Scholar
• Artemov D., Mori N., Okollie B., Bhujwalla Z. M. MR molecular imaging of the her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49: 403–408
   PubMed Web of Science ®Google Scholar
• Funovics M. A., Kapeller B., Hoeller C., Su H., Kunstfeld R., Puig S., Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imag 2004; 22: 0843–0850
   PubMed Web of Science ®Google Scholar
• Aaron J. S., Oh J., Larson T. A., Kumar S., Milner T. E., Sokolov K. V. Increased optical contrast in imaging of epidermal growth factor receptor using magnetically actuated hybrid gold/iron oxide nanoparticles. Opt Expr 2006; 14(29)12930–12943
   PubMedGoogle Scholar
• Gruttner C., Muller K., Teller J., Westphal F., Foreman A., Ivkov R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J Magn Magn Mater 2007; 311: 181–186
   Web of Science ®Google Scholar
• Lee T. M., Oldenburg A. L., Sitafalwalla S., Mark D. L., Luo W., Toublan F. J.J., Suslick K. S., Boppart S. A. Engineered microsphere contrast agent for optical coherence tomography. Opt Lett 2003; 28(17)1546–1548
   PubMed Web of Science ®Google Scholar
• Oldenburg A. L., Crecea V., Rinne S. A., Boppart S. A. Phase-resolved magnetomotive OCT for imaging nanomolar concentrations of magnetic nanoparticles in tissues. Opt Expr 2008; 16(15)11525–11539, Magnetomotive contrast for in vivo optical coherence tomography. Opt Expr 2005, 13(17), 6597–6614.
   PubMed Web of Science ®Google Scholar
• Frangioni J. V. Translating in vivo diagnostics into clinical reality. Nat Biotechnol 2006; 24: 909–913
   PubMed Web of Science ®Google Scholar
• Li C., Wang W., Wu Q., Ke S., Houston J., Sevick-Muraca E., Dong L., Chow D., Charnsangavej C., Gelovani J. G. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl Med Biol 2006; 33: 349–358
   PubMed Web of Science ®Google Scholar
• Adams K. E., Ke S., Kwon S., Liang F., Fan Z., Lu Y. Comparison of visible and nearinfrared wavelength excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 2007; 12: 024017
   PubMed Web of Science ®Google Scholar
• Van Belle P. A., Elennitsas R., Satyamoorthy K., et al. Progression related expression of beta3 integrin in melanomas. Hum Pathol 1999; 30: 562–567
   PubMed Web of Science ®Google Scholar
• Switala-Jelen K., Dabrowska K., Opolski A., Lipinska L., Nowaczyk M., Gorski A. The biological functions of beta3 integrins. Folia Biol (Paraha) 2004; 50: 143–152
   PubMed Web of Science ®Google Scholar
• Trikha M., Timar J., Zacharek A., Nemeth J. A., Cai Y. L., Dome B., Somlai B., Raso E., Ladanyi A., Honn K. V. Role for beta3 integrins in human melanoma growth and survival. Int J Cancer 2002; 101: 156–167
   PubMed Web of Science ®Google Scholar
• Wang X., Ferreira A. M., Shao Q., Laird D. W., Sandig M. Beta3 integrins facilitate matrix interactions during transendothelial migration of PC3 prostate tumor cells. Prostate 2005; 63: 65–80
   PubMed Web of Science ®Google Scholar
• Gruber G., Hess J., Stiefel C., Aebersold D. M., Zimmer Y., Greiner R. H., Studer U., Altermatt H. J., Hlushchuk R., Djonov V. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy. Br J Cancer 2005; 92: 41–46
   PubMed Web of Science ®Google Scholar
• Pignatelli M., Cardillo M. R., Hanby A., Stamp G. Integrins and their accessory adhesion molecules in mammary carcinomas. Hum Pathol 1992; 23: 1159–1166
   PubMed Web of Science ®Google Scholar
• Kawahara E., Ooi A., Nakanishi I. Integrin distribution in gastric carcinoma: association of beta3 and beta5 integrins with tumor invasiveness. Pathol Int 1995; 45: 493–500
   PubMed Web of Science ®Google Scholar
• Albeda S. M., Mette S. A., Elder D. E., Stewart R., Damjanovich L., Herlyn M., Buck C. A. Integrin distribution in malignant-melanoma: association of the beta3 subunit with tumor progression. Cancer Res 1990; 50: 6757–6764
   PubMed Web of Science ®Google Scholar
• Gingras M. C., Roussel E., Bruner J. M., Branch C. D., Moser R. P. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995; 57: 143–153
   PubMed Web of Science ®Google Scholar
• Bloch S., Xu B., Ye Y., et al. Targeting beta-3 integrin using a linear hexapeptide labeled with a near-infrared fluorescent molecular probe. Mol Pharm 2006; 3(5)539–549
   PubMedGoogle Scholar
• Krissansen G. W., Elliott M. J., Lucas C. M., Stomski F. C., Berndt M. C., Cheresh D. A., Lopez A. F., Burns G. F. Identification of a novel integrin αv subunit expressed on cultured monocytes (macrophages). J Biol Chem 1990; 265: 823–830
   PubMed Web of Science ®Google Scholar
• Cheresh D. A., Smith J., Cooper H., Quaranta V. A novel vitronectin receptor integrin is responsible for distinct adhesive properties of carcinoma cells. Cell 1989; 57: 59–69
   PubMed Web of Science ®Google Scholar
• Filardo E. J., Cheresh D. A. A β turn in the cytoplasmic tail of the integrin αv subunit influences conformation and ligand binding of αvβ3. J Biol Chem 1997; 269(6)4641–4647
   Google Scholar
• Felding-Habermann B., Mueller B. M., Romerdahl C. A., Cheresh D. A. Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89(6)2018–2022
   PubMed Web of Science ®Google Scholar
• Albelda S. M., Mette S. A., Elder D. E., Stewart R. M., Damjanovich L., Herlyn M., Clayton A. Integrin distribution in malignant melanoma. Cancer Res 1990; 50: 6757–6764
   PubMed Web of Science ®Google Scholar
• Blystone S. D., Slater S. E., Williams M. P., Crow M. T., Brown E. J. A molecular mechanism of integrin crosstalk. J Cell Biol 1999; 145: 889–897
   PubMed Web of Science ®Google Scholar
• Schwartz M. A., Ginsberg M. H. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol 2002; 4: E65–E68
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79(7)1157–1164
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Strömblad S., Klemke R., Visscher D., Sarkar F. H., Cheresh D. A. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96(4)1815–1822
   PubMed Web of Science ®Google Scholar
• Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A., Cheresh D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270(5241)1500–1502
   PubMed Web of Science ®Google Scholar